-
公开(公告)号:MX2021013993A
公开(公告)日:2021-12-10
申请号:MX2021013993
申请日:2020-05-14
Applicant: VERTEX PHARMA
Inventor: LOOKER ADAM , ROEPER STEFANIE , FANNING LEV TYLER DEWEY , HURLEY DENNIS JAMES , JONES PETER , SHI YI , COTTRELL KEVIN MICHAEL , MAXWELL JOHN PATRICK , RONKIN STEVEN M , GIROUX SIMON , STAVROPOULOS KATHY , BRODNEY MICHAEL AARON , MEDEK ALES , SHRESTHA MUNA , ZAKY MARIAM , NUHANT PHILIPPE MARCEL , BLIGH CAVAN MCKEON , GAGNON KEVIN JAMES , HOOD SARAH CAROL , RODAY SETU , SAWANT RUPA , TANG QING , BANDARAGE UPUL KEERTHI , DAMAGNEZ VERONIQUE , GREY JR RONALD LEE , HALL AMY BETH , SWETT REBECCA JANE , TAPLEY TIMOTHY LEWIS , XU JINWANG , BOUCHER DIANE , BOYD MICHAEL JOHN , CLARK MICHAEL PHILIP , FIMOGNARI ROBERT FRANCIS , FLEMING GABRIELLE SIMONE , GUIDO SAMANTHA , JOHNSON JR MAC ARTHUR , KESAVAN SARATHY , LAI MEI-HSIU , LIU SIYING , MAXWELL BRAD , OVERHOFF KIRK ALAN , SPOSATO MARISA , THOMSON STEPHEN , GARCIA BARRANTES PEDRO , GIACOMETTI ROBERT
IPC: A61K31/429 , A61K31/4162 , A61P1/16 , A61P11/00 , C07D231/56 , C07D487/04 , C07D498/18 , C07D513/04
Abstract: La descripción proporciona compuestos útiles para tratar la deficiencia de alfa-1 antitripsina (AATD), de acuerdo con la fórmula (I), tautómeros de estos, sales farmacéuticamente aceptables de los compuestos, sales farmacéuticamente aceptables de los tautómeros, derivados deuterados de los compuestos, derivados deuterados de los tautómeros y derivados deuterados de las sales, formas sólidas de esos compuestos y procesos para preparar esos compuestos. (ver Fórmula).
-
公开(公告)号:CR20210383A
公开(公告)日:2021-09-22
申请号:CR20210383
申请日:2019-12-17
Applicant: VERTEX PHARMA
Inventor: NANTHAKUMAR SUGANTHINI S , GAGNON KEVIN , DAKIN LESLIE A , HU KAN-NIAN , MEDEK ALES , SHI YI , SHRESTHA MUNA , DENIS FRANCOIS , KRUEGER ELAINE B , WITKOS FAITH , CAO JINGRONG , HAMEL MARTINE , LEDFORD BRIAN , NICOLAS OLIVIER , COME JON H , DORSCH WARREN A , FORTIER ANNE , ROSE PETER , SAYEGH CAMIL , WANG TIANSHENG , BRODNEY MICHAEL , SENTER TIMOTHY J
IPC: A61K31/4025 , A61P13/12 , C07D403/12
Abstract: La descripción proporciona al menos una entidad seleccionada de compuestos de la fórmula ( I ), formas en estado sólido de ellos, composiciones que los comprenden y métodos que los usan, incluyendo el uso en el tratamiento de glomeruloesclerosis segmentaria focal (FSGS) y/o enfermedad renal no diabética (NDKD).
-
公开(公告)号:SI3551622T1
公开(公告)日:2021-02-26
申请号:SI201730537
申请日:2017-12-08
Applicant: VERTEX PHARMA
Inventor: ABELA ALEXANDER RUSSELL , ALCACIO TIMOTHY , ANDERSON COREY , ANGELL PAUL TIMOTHY , BAEK MINSON , CLEMENS JEREMY J , CLEVELAND THOMAS , FERRIS LORI ANN , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY , GULEVICH ANTON , HADIDA RUAH SARA SABINA , HSIA CLARA KUANG-JU , HUGHES ROBERT M , JOSHI PRAMOD VIRUPAX , KANG PING , KESHAVARZ-SHOKRI ALI , KHATUYA HARIPADA , KRENITSKY PAUL JOHN , MCCARTNEY JASON , MILLER MARK THOMAS , PARASELLI PRASUNA , PIERRE FABRICE JEAN DENIS , SHI YI , SHRESTHA MUNA , SIESEL DAVID ANDREW , STAVROPOULOS KATHY , TERMIN ANDREAS P , UY JOHNNY , VAN GOOR FREDRICK F , YOUNG TOMOTHY JOHN , ZHOU JINGLAN
IPC: C07D401/00 , A61K31/00 , A61P11/00 , C07D231/00
-
公开(公告)号:RS61150B1
公开(公告)日:2020-12-31
申请号:RSP20201477
申请日:2017-12-08
Applicant: VERTEX PHARMA
Inventor: ABELA ALEXANDER RUSSELL , ALCACIO TIMOTHY , ANDERSON COREY , ANGELL PAUL TIMOTHY , BAEK MINSON , CLEMENS JEREMY J , CLEVELAND THOMAS , FERRIS LORI ANN , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY , GULEVICH ANTON , HADIDA RUAH SARA SABINA , HSIA CLARA KUANG-JU , HUGHES ROBERT M , JOSHI PRAMOD VIRUPAX , KANG PING , KESHAVARZ-SHOKRI ALI , KHATUYA HARIPADA , KRENITSKY PAUL JOHN , MCCARTNEY JASON , MILLER MARK THOMAS , PARASELLI PRASUNA , PIERRE FABRICE JEAN DENIS , SHI YI , SHRESTHA MUNA , SIESEL DAVID ANDREW , STAVROPOULOS KATHY , TERMIN ANDREAS P , UY JOHNNY , VAN GOOR FREDRICK F , YOUNG TOMOTHY JOHN , ZHOU JINGLAN
IPC: C07D401/14 , A61K31/455 , A61P11/00 , C07D231/20 , C07D401/04
-
公开(公告)号:UY38696A
公开(公告)日:2020-11-30
申请号:UY38696
申请日:2020-05-13
Applicant: VERTEX PHARMA
Inventor: JONES PETER , NUHANT PHILIPPE MARCEL , BANDARAGE UPUL KEERTHI , BLIGH CAVAN MCKEON , GAGNON KEVIN JAMES , BOYD MICHAEL JOHN , GIROUX SIMON , GREY JR RONALD LEE , HALL AMY BETH , HOOD SARAH CAROL , HURLEY DENNIS JAMES , JOHNSON JR , KESAVAN SARATHY , LOOKER ADAM , MAXWELL JOHN PATRICK , MEDEK ALES , RODAY SETU , ROEPER STEFANIE , SAWANT RUPA , SHI YI , SWETT REBECCA JANE , TANG QING , TAPLEY TIMOTHY LEWIS , XU JINWANG , BOUCHER DIANE , CLARK MICHAEL PHILIP , DAMAGNEZ VERONIQUE , FANNING LEV TYLER DEWEY , FIMOGNARI ROBERT FRANCIS , FLEMING GABRIELLE SIMONE , GARCIA BARRANTES PEDRO MANUEL , GIACOMETTI ROBERT DANIEL , GUIDO SAMANTHA , LAI MEI-HSIU , LIU SIYING , MAXWELL BRAD , OVERHOFF KIRK ALAN , RONKIN STEVEN M , SHRESTHA MUNA , SPOSATO MARISA , STAVROPOULOS KATHY , THOMSON STEPHEN , ZAKY MARIAM , BRODNEY MICHAEL AARON
IPC: A61P1/16 , A61K31/4162 , A61P11/00 , C07D487/14 , C07D498/18
Abstract: La descripción proporciona compuestos útiles para tratar la deficiencia de alfa-1 antitripsina (AATD), de acuerdo con la fórmula (I), tautómeros de estos, sales farmacéuticamente aceptables de los compuestos, sales farmacéuticamente aceptables de los tautómeros, derivados deuterados de los compuestos, derivados deuterados de los tautómeros y derivados deuterados de las sales, formas sólidas de esos compuestos y procesos para preparar esos compuestos.
-
公开(公告)号:HRP20191641T1
公开(公告)日:2019-12-13
申请号:HRP20191641
申请日:2019-09-12
Applicant: VERTEX PHARMA
Inventor: CHARRIER JEAN-DAMIEN , STUDLEY JOHN , PIERARD FRANCOISE YVONNE THEODORA MARIE , DURRANT STEVEN JOHN , LITTLER BENJAMIN JOSEPH , HUGHES ROBERT MICHAEL , SIESEL DAVID ANDREW , ANGELL PAUL , URBINA ARMANDO , SHI YI
IPC: C07D413/04 , A61K31/497 , A61P35/00
-
公开(公告)号:HRP20191525T1
公开(公告)日:2019-11-29
申请号:HRP20191525
申请日:2019-08-26
Applicant: VERTEX PHARMA
Inventor: NTI-ADDAE KWAME W , WALDO MICHAEL , O'NEIL SIMON ADAM , VAN ALSTEN JOHN GREGG , MACIKENAS DAINIUS , MUDUNURI PRAVEEN , SHI YI , LEDEBOER MARK WILLEM , JURKAUSKAS VALDAS , MEDEK ALES , JONES STEVEN , BYRN RANDAL , ASMAL MOHAMMED , ROBERTSON SARAH MARIE , TSAI WANJUNG
IPC: C07D403/04 , A61K31/506 , A61P31/16 , C07D471/04
-
公开(公告)号:HUE044667T2
公开(公告)日:2019-11-28
申请号:HUE14802787
申请日:2014-11-12
Applicant: VERTEX PHARMA
Inventor: NTI-ADDAE KWAME , WALDO MICHAEL , O'NEIL SIMON , VAN ALSTEN JOHN , MACIKENAS DAINIUS , MUDUNURI PRAVEEN , SHI YI , LEDEBOER MARK , JURKAUSKAS VALDAS , MEDEK ALES , JONES STEVEN , BYRN RANDAL , ASMAL MOHAMMED , ROBERTSON SARAH , TSAI WANJUNG
IPC: A61P31/16
-
公开(公告)号:NZ737090A
公开(公告)日:2019-05-31
申请号:NZ73709012
申请日:2012-09-28
Applicant: VERTEX PHARMA
Inventor: DURRANT STEVEN , CHARRIER JEAN-DAMIEN , STUDLEY JOHN , PIERARD FRANCOISE YVONNE THEODORA MARIE , LITTLER BENJAMIN JOSEPH , HUGHES ROBERT MICHAEL , SIESEL DAVID ANDREW , URBINA ARMANDO , SHI YI , ANGELL PAUL
IPC: C07D413/04 , A61K31/497 , A61P35/00
Abstract: The present disclosure relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present disclosure also relates to compounds useful as inhibitors of ATR protein kinase. The disclosure relates to pharmaceutically acceptable compositions comprising the compounds; methods of treating of various diseases, disorders, and conditions using the compounds; processes for preparing the compounds; intermediates for the preparation of the compounds; and solid forms of the compounds. The compounds have formula (I) or (II) wherein the variables are as defined herein.
-
公开(公告)号:AU2014348840A1
公开(公告)日:2016-05-26
申请号:AU2014348840
申请日:2014-11-12
Applicant: VERTEX PHARMA
Inventor: NTI-ADDAE KWAME W , WALDO MICHAEL , O'NEIL SIMON ADAM , VAN ALSTEN JOHN GREGG , MACIKENAS DAINIUS , MUDUNURI PRAVEEN , SHI YI , LEDEBOER MARK WILLEM , JURKAUSKAS VALDAS , MEDEK ALES , JONES STEVEN , BYRN RANDAL , ASMAL MOHAMMED , ROBERTSON SARAH MARIE , TSAI WANJUNG
IPC: C07D403/04 , A61K31/506 , A61P31/16 , C07D471/04
Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: are Form A of HCl salt of Compound (1)·1/2&EEgr;
-
-
-
-
-
-
-
-
-